Mesenchymal Stem Cell-Derived Extracellular Vesicles: Pleiotropic Impacts on Breast Cancer Occurrence, Development, and Therapy

Yiling Guo, Yujia Zhai, Longyuan Wu, Yazhuo Wang, Puzhen Wu, Lixia XiongInternational Journal of Molecular Sciences 2022 · DOI

TL;DR

This review explores the complex, dual role of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) in breast cancer (BC). MSC-EVs can both promote and inhibit BC progression, acting as key communicators in the tumor microenvironment and offering promising avenues for novel therapeutic strategies, particularly as drug delivery vehicles.

What Problem Does This Paper Address?

Breast cancer (BC) remains a significant global health challenge, characterized by high morbidity and mortality. While conventional treatments have advanced, they often face limitations like drug resistance and severe side effects. The tumor microenvironment (TME) plays a critical role in BC progression, and mesenchymal stem cells (MSCs) are key players within it. This paper addresses the need to understand the intricate mechanisms by which MSCs influence BC, specifically focusing on their secreted extracellular vesicles (EVs), and how these MSC-EVs can be leveraged for more effective BC treatment. The complexity arises from MSC-EVs exhibiting both pro-tumorigenic and anti-tumorigenic effects, necessitating a comprehensive review to clarify their multifaceted roles.

Methods

This paper is a comprehensive review of existing literature. It synthesizes findings from numerous studies that have investigated the roles of MSC-EVs in various aspects of breast cancer development and treatment. The authors systematically analyze research on:

  • EV Biogenesis and Classification: Explaining how EVs, including exosomes and microvesicles, are formed and their general characteristics.
  • MSC-EVs in BC Progression: Reviewing studies that examine the impact of MSC-EVs on cell proliferation, autophagy, apoptosis, aggressiveness, angiogenesis, immune regulation, dormancy, and drug resistance.
  • MSC-EVs as Therapeutic Agents: Analyzing research on the use of MSC-EVs as drug carriers for BC therapy, including naturally occurring EVs, engineered EVs, and EVs loaded with exogenous cargos.

The review relies on data from in vitro cell culture experiments, in vivo animal models, and clinical observations reported in the literature.

Datasets

Not discussed in the paper. This is a review article, synthesizing existing research rather than presenting new experimental data or datasets.

Key Insights and Ideas

  • Dual Nature of MSC-EVs: The most striking insight is that MSC-EVs are not simply "good" or "bad" for BC. They can act as both promoters and inhibitors of tumor growth, metastasis, and drug resistance, depending on the specific context, MSC source, and the cargo within the EVs.
  • EVs as Key Intercellular Messengers: MSC-EVs are crucial for communication within the TME, transferring molecules like miRNAs, proteins, and lipids that can reprogram recipient cells, including BC cells and other stromal cells.
  • Therapeutic Potential as Drug Carriers: MSC-EVs possess inherent properties like biocompatibility and low immunogenicity, making them excellent candidates for drug delivery systems. They can be engineered to target specific tumor sites and deliver therapeutic payloads more effectively than conventional methods.
  • Complexity of MSC Source and Cargo: The origin of the MSCs (e.g., adipose tissue, bone marrow, umbilical cord) and the specific molecules (cargo) they package into EVs significantly influence their effects on BC. This variability explains some of the contradictory findings in the literature.
  • Role in Pre-Metastatic Niche (PMN) Formation: MSC-EVs are implicated in creating a favorable microenvironment (PMN) at distant sites, preparing them for the colonization of metastatic BC cells.

Key Results

The review highlights a wide range of effects attributed to MSC-EVs:

  • Cell Proliferation: MSC-EVs can promote BC cell proliferation by activating pathways like ERK and Wnt, but some MSC-EVs can also inhibit proliferation.
  • Apoptosis and Autophagy: MSC-EVs can induce apoptosis to exert anti-cancer effects, but they can also promote autophagy, which can sometimes suppress apoptosis.
  • Aggressiveness and Metastasis: MSC-EVs can promote invasion and migration by influencing EMT pathways, but certain miRNAs delivered by MSC-EVs can suppress metastasis.
  • Angiogenesis: While some studies suggest MSC-EVs can promote angiogenesis, the majority of evidence indicates an inhibitory effect, primarily through miRNA-mediated downregulation of VEGF.
  • Immune Regulation: MSC-EVs can act as both stimulatory and inhibitory mediators of immune responses in BC, influencing immune cell differentiation and function.
  • Dormancy: MSC-EVs can induce a dormant state in BC cells, which is crucial for metastasis and recurrence.
  • Drug Resistance: MSC-EVs show a paradoxical role in drug resistance, with some studies indicating they promote chemoresistance while others show they can enhance sensitivity to certain drugs.
  • Therapeutic Applications: MSC-EVs loaded with therapeutic agents (e.g., miRNAs, chemotherapeutics) have demonstrated improved efficacy and reduced side effects in preclinical studies, including targeting brain metastasis.

Limitations and Future Work

  • Contradictory Findings: The authors acknowledge that contradictory findings regarding the effects of MSC-EVs are common. They attribute this to variations in experimental protocols, MSC sources, EV isolation and characterization methods, and the specific cargo within the EVs.
  • Preclinical Stage: Most of the research discussed is in the preclinical stage. Further basic research and technological advancements are needed to fully exploit the potential of MSC-EVs.
  • Need for Standardization: There is a need for standardized methods for EV isolation, characterization, and cargo analysis to ensure reproducibility and comparability of results.
  • Targeted Delivery and Efficacy: Developing strategies to enhance the drug delivery capabilities, target specificity, and non-cytotoxic effects of MSC-EVs is crucial for their clinical translation.
  • PMN Formation in Other Organs: More research is needed on the role of MSC-EVs in forming pre-metastatic niches in organs beyond bone marrow, which could lead to breakthroughs in treating distant metastasis.
  • Clinical Translation: Bridging the gap between preclinical findings and clinical application requires further investigation into the safety, efficacy, and optimal therapeutic strategies for MSC-EV-based therapies.

Summary updated

Abstract

Breast cancer (BC) is one of the most devastating cancers, with high morbidity and mortality, among the female population worldwide. In BC, mesenchymal stem cells (MSCs), as pluripotent stromal stem cells, play a significant role in TME formation and tumor progression. Recently, an increasing number of studies have demonstrated that extracellular vesicles (EVs) are essential for the crosstalk between MSCs and BC cells. MSC-derived EVs (MSC-EVs) can deliver a diversity of molecules, including lipids, proteins, and nucleic acids, etc., to target cells, and produce corresponding effects. Studies have demonstrated that MSC-EVs exert both inhibitory and promotive effects in different situations and different stages of BC. Meanwhile, MSC-EVs provide novel therapeutic options for BC, such as EVs as carriers for drug delivery. Therefore, in this review, we summarize the role of MSC-EVs in BC progression and application in clinical treatment, in the hope of providing a basis for further research.
BibTeX
@article{guo2022mesenchymal,
  author = {Yiling Guo and Yujia Zhai and Longyuan Wu and Yazhuo Wang and Puzhen Wu and Lixia Xiong},
  title = {{Mesenchymal Stem Cell-Derived Extracellular Vesicles: Pleiotropic Impacts on Breast Cancer Occurrence, Development, and Therapy}},
  journal = {International Journal of Molecular Sciences},
  year = {2022},
  doi = {10.3390/ijms23062927},
}
Figure